PF-06669571 In Subjects With Idiopathic Parkinson's Disease
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple
 doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study
 will assess whether PF-06669571 is able to demonstrate superior efficacy compared with
 placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.
Inclusion Criteria:

 -  Subjects must have a clinical diagnosis of idiopathic Parkinson's disease and presence
 of at least 2 out of 3 cardinal characteristics (tremor, rigidity and/or
 bradykinesia).

 -  Must be Hoehn & Yahr Stage II-III inclusive and experiencing motor fluctuations in the
 form of end-of-dose wearing off during the morning hours or early morning akinesia.

 -  Subjects should be able to recognize their "wearing off" symptoms and verify that they
 usually improve after their next dose of Parkinson's disease medication. Subjects
 should be able to recognize drug-induced dyskinesias and verify whether or not they
 are troublesome.

 Exclusion Criteria:

 - History or clinical features consistent with an atypical parkinsonian syndrome, (for
 example: ataxia, dystonia, clinically significant orthostatic hypotension.